| Male (%) |
34 (71%) |
| Median age (IQR) |
64 (60 - 71) yrs |
| ASA 1/2/3 |
11 (23%)/26 (54%)/11 (23%) |
| Median BMI (IQR) |
27.5 (23 - 29.5) |
| Vascular co-morbidity (%) |
13 (27%) |
| Neoadjuvant therapy |
| Short course radiotherapy (%) |
17 (35%) |
| Long course chemoradiotherapy (%) |
31 (65%) |
| T stage |
| T0/T1 |
16 (33%) |
| T2 |
10 (21%) |
| T3 |
21 (44%) |
| T4 |
1 (2%) |
| N stage |
| N0 |
32 (67%) |
| N1 |
13 (27%) |
| N2 |
3 (6%) |
| Median number of lymph nodes sampled (IQR) |
9 (7 - 15) |
| Median number of involved nodes (IQR) |
2 (1 - 3) |
| Median lymph node ratio in N+ve cases (IQR) |
0.16 (0.08 - 0.41) |
| Tumour differentiation |
| Complete response |
6 (13%) |
| Well/Moderate |
41 (85%) |
| Poor |
1 (2%) |
| Median tumour size (IQR) |
17 (11 - 30) mm |
| R1 rate (%) |
1 (2%) |
| Circumferential margin involved |
1 (2%) |
| Distal margin involved |
0 |
| Mode of surgery |
| Open |
43 (90%) |
| Laparoscopic |
5 (10%) |
| Type of defunctioning stoma |
| Loop ileostomy |
47 (98%) |
| Loop transverse colostomy |
1 (2%) |